Astrazeneca ADR Stock
€78.50
Your prediction
Financial data and news for AstraZeneca
sharewise wants to provide you with the best news and tools for AstraZeneca, so we directly link to the best financial data sources.
Financials
News
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Key Points
- Interested in Innate Pharma S.A. Sponsored ADR? Here are five stocks we like better.
- Innate Pharma raised €30 million to fund its lacutamab, IPH4502 and preclinical ADC programs
Royalty Pharma Q2 Earnings Call Highlights
Key Points
- Interested in Royalty Pharma PLC? Here are five stocks we like better.
- Royalty Pharma raised its 2026 outlook for the second consecutive quarter, now forecasting portfolio receipts
SOPHiA GENETICS Q2 Earnings Call Highlights
Key Points
- Interested in SOPHiA GENETICS SA? Here are five stocks we like better.
- Q2 revenue rose 27% to $23.3 million, while patient analyses reached a record 115,000 and the adjusted EBITDA
Astrazeneca Q2 Earnings Call Highlights
Key Points
- Interested in Astrazeneca Plc? Here are five stocks we like better.
- Solid first-half performance: AstraZeneca reported revenue growth of 6% at constant exchange rates and 11%
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Key Points
- Interested in Astrazeneca Plc? Here are five stocks we like better.
- Wainua failed its CARDIO-TTRansform Phase 3 trial by showing no additive benefit for patients already taking
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage
Key Points
- Interested in Astrazeneca Plc? Here are five stocks we like better.
- AstraZeneca updated its 2030 sustainability targets, lowering its Scope 3 emissions goal to a 35% reduction from
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Key Points
- Interested in Inovio Pharmaceuticals, Inc.? Here are five stocks we like better.
- Shareholders approved all proposals at Inovio’s 2026 annual meeting, including the election of eight
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build
Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance
Innate Pharma Q1 Earnings Call Highlights
Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate
As Investors Flee U.S. Equities, This Global ETF Is Outperforming
Since the start of the year, investors have been vacating U.S. stocks and exchange-traded funds (ETFs) in a broad-based, risk-off strategy that has benefited safe-haven assets like gold and silver
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI (NASDAQ: TEM) have gone on a wild rollercoaster ride. The firm’s initial public offering price
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
In recent weeks, two pharmaceutical stocks, AstraZeneca (NYSE: AZN) and Bristol Myers Squibb (NYSE: BMY), have become the subject of merger rumors. At the start of the month, the Financial Times
Cathie Wood Just Bet Big on This Biotech Stock
Cathie Wood's ARK Genomic Revolution ETF (NYSEMKT: ARKG) focuses on companies in the genomics sector, especially in healthcare. Since the beginning of July, Wood has, through this Ark Invest
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
According to an SEC filing dated May 15, 2026, Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in the first quarter. The estimated value of the trade was $4.11
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026
How decision velocity closes the gap between insight and action in complex, fast-moving supply chains
ANTWERPEN, BE / ACCESS Newswire / May 7, 2026 / OMP, a leader in AI-powered supply
P&G and OMP Showcase the Path to Autonomous, Decision-Centric Planning at Gartner Supply Chain Symposium/Xpo 2026
How decision velocity is closing the gap between insight and action across one of the world's most complex value chains
ATLANTA, GA / ACCESS Newswire / April 14, 2026 / OMP, a leader in